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OBJECTIVES To assess the relation of left ventricular (LV) and left atrial (LA) dimensions, ejection fraction
(EF) and LV mass to subsequent clinical outcome of patients with LV dysfunction enrolled
in the Studies of Left Ventricular Dysfunction (SOLVD) Registry and Trials.
BACKGROUND Data are lacking on the relation of LV mass to prognosis in patients with LV dysfunction and
on the interaction of LV mass with other measurements of LV size and function as they relate
to clinical outcome.
METHODS A cohort of 1,172 patients enrolled in the SOLVD Trials (n 5 577) and Registry (n 5 595)
had baseline echocardiographic measurements and follow-up for 1 year.
RESULTS After adjusting for age, New York Heart Association (NYHA) functional class, Trial vs. Registry
and ischemic etiology, a 1-SD difference in EF was inversely associated with an increased risk of
death (risk ratio, 1.62; p 5 0.0008) and cardiovascular (CV) hospitalization (risk ratio, 1.59; p 5
0.0001). Consequently, the other echo parameters were adjusted for EF in addition to age,
NYHA functional class, Trial vs. Registry and ischemic etiology. A 1-SD difference in LV mass
was associated with increased risk of death (risk ratio of 1.3, p 5 0.012) and CV hospitalization
(risk ratio of 1.17, p 5 0.018). Similar results were observed with the LA dimension (mortality
risk ratio, 1.32; p , 0.02; CV hospitalizations risk ratio, 1.18; p , 0.04). Likewise, LV mass
$298 g and LA dimension $4.17 cm were associated with increased risk of death and CV
hospitalization. An end-systolic dimension .5.0 cm was associated with increased mortality only.
A protective effect of EF was noted in patients with LV mass $298 g (those in the group with
EF .35% had lower mortality) but not in the group with LV mass ,298 g.
CONCLUSIONS In patients with LV dysfunction enrolled in the SOLVD Registry and Trials, increasing levels
of hypertrophy are associated with adverse events. A protective effect of EF was noted in
patients with LV mass $298 g (those in the group with EF .35% fared better) but not in
the group with LV mass ,298 g. These data support the development and use of drugs that
can inhibit hypertrophy or alter its characteristics. (J Am Coll Cardiol 2000;35:1237–44) ©
2000 by the American College of Cardiology
Over the past two decades, a number of physiologic,
biochemical and clinical variables have been identified as
important contributors to the prognosis of patients with left
ventricular (LV) dysfunction. Included among them are the
following: advanced age, diabetes, etiology of LV dysfunc-
tion and symptomatic status (1–3), LV size and parameters
of systolic and diastolic function (3–8), pulmonary pressures
(9,10), ventricular arrhythmias (11), electrolyte abnormali-
ties and neurohormonal alterations (4,12). More recently,
LV hypertrophy has been proved to be a powerful and
independent predictor of increased morbidity and mortality
in population studies as well as in patients with systemic
hypertension or coronary artery disease (13–19). Further-
more excessive hypertrophy has been associated with devel-
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opment of LV dysfunction in animal models and in patients
with hypertension or other forms of heart disease (20–23).
However, the influence of hypertrophy on the prognosis of
patients with systolic LV dysfunction and/or heart failure is
not well described.
The Studies of Left Ventricular Dysfunction (SOLVD)
trials were designed to assess the effects of the angiotensin-
converting enzyme (ACE) inhibitor, enalapril, in patients
with LV dysfunction regardless of the presence or absence
of heart failure symptoms (24). Concomitant with the
SOLVD trials, a Registry of patients with LV systolic
dysfunction was established (25). A cohort of patients from
the Trials and Registry participated in substudies that
included echocardiographic evaluation of LV function at the
time of enrollment. All patients were observed by the
SOLVD investigators for a minimum of one year. The
present investigation represents an analysis of these data
with the purpose of determining the relation between
echocardiographic measurements of LV size and function,
LV mass and left atrial (LA) size to one-year mortality and
rate of cardiovascular (CV) hospitalizations.
METHODS
Patient population. The SOLVD Registry consisted of
6,273 patients with one of the following entry criteria: an
ejection fraction (EF) #45% measured by echocardiogra-
phy, contrast ventriculography or radionuclide techniques,
or a hospitalization for congestive heart failure (CHF)
confirmed by radiographic evidence of pulmonary venous
congestion, regardless of the resting EF (25). A subgroup of
898 patients from 21 participating centers were enrolled in
a Registry substudy to investigate the relation of clinical,
functional, structural and neurohormonal variables to mor-
bidity and mortality. These patients were randomly selected
within strata organized according to varying etiologies of
LV dysfunction so as to reduce the frequency of ischemic
and hypertensive etiologies relative to other forms of heart
diseases. The demographic and clinical characteristics of the
898 patients have been described previously (25). They all
underwent a baseline two-dimensional echocardiogram.
One third of these patients were randomized to the
SOLVD main Trials. The SOLVD Trials enrolled 6,797
patients with a resting EF #35%. Patients with history of
overt heart failure were enrolled in the Treatment Trial and
those with no history of heart failure were entered into the
Prevention Trial (26,27). A subset of 311 patients (216 from
the Prevention and 95 from the Treatment Trial) had
baseline echocardiograms as part of a substudy that evalu-
ated the effects of enalapril therapy on LV size, hypertrophy
and function (28,29). For the purpose of this investigation,
we added these patients to the Registry Substudy, increasing
the total sample to 1,209 patients.
The following events were registered: all cause mortality,
CV mortality, heart failure death, total hospitalization, CV
hospitalizations and heart failure hospitalizations. Follow-up in
the Registry patients was limited to one year.
Echocardiographic evaluation. The study protocol was
approved by the Institutional Review Boards at each of the
participating centers and each patient signed an informed
consent form. A two-dimensional echocardiographic exam-
ination was performed with each patient lying in the left
lateral recumbent position. The views obtained consisted of
the parasternal long and short axis, and the apical four- and
two-chamber view. A minimum of 10 cardiac cycles were
recorded in each view. All video tapes were copied and the
original sent for analysis to the SOLVD echocardiographic
core laboratory at Baylor College of Medicine, The Meth-
odist Hospital, Houston, Texas.
All of the LV and LA measurements were taken directly
from the two-dimensional images by experienced observers
blinded to any clinical information or to the assignment of
Trial patients into the Treatment or Prevention trial, or the
placebo or enalapril limb. Measurements were made using
an off-line computerized analysis station equipped with
internal calipers (Digisonics, Inc., Houston, Texas) using
techniques previously described in detail (28). In brief, the
end-diastolic and systolic LV dimensions, the thickness of
the septum and posterior wall and the LA systolic dimen-
sion were measured in the parasternal long axis view. In
.50% of studies, the use of a low parasternal window
resulted in an angulated short axis appearance of the LV
that precluded the use of either the area-length or the
truncated ellipsoid method of deriving LV mass (30). LV
mass was therefore estimated by applying the cube formula
to the end-diastolic dimension and the septal and posterior
wall thickness measured in the parasternal long axis view
(28). LV mass was reported in absolute terms given that
height was not consistently available and thus correction for
body mass could not be obtained. Accurate measurement of
end-diastolic and end-systolic volumes by two-dimensional
echocardiography requires apical views that avoid foreshort-
ening of the LV cavity (30), otherwise the results are
inaccurate. Unfortunately, this level of technical quality
could not be achieved consistently in the 18 centers partic-
ipating in the Registry. Consequently, LV volumes were not
incorporated into the analysis. Instead, EF was derived
using the multiple diameter method that does not require
volumetric measurements (31).
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
CHF 5 congestive heart failure
CV 5 cardiovascular
EF 5 ejection fraction
LA 5 left atrium
LV 5 left ventricle
NYHA 5 New York Heart Association
SD 5 standard deviation
SOLVD 5 Studies of Left Ventricular Dysfunction
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Data analysis. All of the echocardiographic data were
stored in computer and sent to the data coordinating center
at the University of North Carolina, Chapel Hill, where
they were stored with demographic and clinical information
that included age, gender, New York Heart Association
(NYHA) classification, heart rate and systemic blood pres-
sure. Follow-up data included all-cause mortality, deaths
from CV causes and from heart failure (CHF), number of
hospitalizations, CV hospitalizations and CHF hospitaliza-
tions. Given that most deaths and hospitalizations were
cardiovascular in nature, we have limited the statistical
analyses to include only all-cause mortality and CV hospi-
talizations, although descriptive statistics for other events
are included in this report. The nonparametric Wilcoxon
two-sample test was used for comparisons of continuous
variables between Trial and Registry patients. The Fisher
exact test or the Pearson chi-square statistic was used to
compare distributions of nominal variables. The relation
between a 1-SD difference in an echocardiographic param-
eter between any two patients and risk of death and CV
hospitalization was evaluated using Cox proportional hazard
regression analysis. The association of an echo parameter
above and below its mean value to mortality and rate of CV
hospitalization was also examined by Cox proportional
hazards regression. All of the analyses relating an echo
parameter to an event rate were adjusted initially for age,
NYHA functional class, Trial versus Registry assignment
and ischemic etiology. Subsequently the analyses were
adjusted for EF in addition to the other factors (see
following text). Kaplan-Meier survival plots were also con-
structed.
RESULTS
Of the 1,209 patients, 1,172 had at least one of the
echocardiographic measurements listed in Table 1 available
for analysis. The clinical characteristics of these patients are
Table 1. Echocardiographic Measurements at Baseline
n Mean 6 SD Median Range
LV end-diastolic dimension (cm)
All patients 1,077 6.0 6 0.97 6.0 3.90–9.10
Trial 535 6.22 6 0.89* 6.2 3.91–9.10
Registry 542 5.79 6 0.99 5.7 3.90–9.00
LV end-systolic dimension (cm)
All patients 1,068 5.0 6 1.19 4.93 2.10–8.50
Trial 529 5.30 6 1.04* 5.32 2.10–8.50
Registry 539 4.62 6 1.23 4.50 2.10–8.30
LVEF (%)
All patients 1,049 34.5 6 13.4 32 5–79
Trial 512 30.2 6 10* 29 10–70
Registry 537 38.5 6 15.1 36 5–79
LV mass (g)
All patients 1,045 298 6 103 282 86–1,023
Trial 521 290 6 99† 275 86–1,023
Registry 524 306 6 107 288 102–866
LA dimension (cm)
All patients 1,077 4.17 6 0.82 4.1 2–10.5
Trial 536 4.15 6 0.73 4.1 2.3–7
Registry 541 4.18 6 0.89 4.1 2–10.5
*p , 0.0001 Trial vs. Registry. †p 5 0.02 Trial vs. Registry.
LV 5 left ventricle; EF 5 ejection fraction; LA 5 left atrium.
Table 2. Clinical Characteristics of Study Population
All
Patients
(n 5 1,172)
Trial
Patients
(n 5 577)
Registry
Patients
(n 5 595)
Age (yr) 59.7 6 11.6 59 6 11 60.4 6 12
Weight (kg) 79.9 6 16.8 81.7 6 15.9* 78.2 6 17.43
Male subjects
(%)
80 86* 74
Race (%)
White 86.2 85.2 87.1
Black 11.6 11.8 11.4
Other 2.2 3 1.5
CHF etiology
(%)
Ischemic 58.3 68.7 48.3†
Nonischemic 36.6 21.2 51.7†
Unknown 5.1 10.1
NYHA class
(%)
I 38.8 44.5 33.2
II 46.3 44.5 48
III–IV 15 11* 18.8
*p # 0.001 Trial vs. Registry patients.
†Difference between Trials and Registry was by design.
CHF 5 congestive heart failure; NYHA 5 New York Heart Association.
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listed in Table 2. The mean age was 59.7 years, 80% of the
patients were male and white was the predominant race.
Ischemic heart disease was the most common etiology of
LV dysfunction. Most patients (85%) were in NYHA
functional class I or II at the time of enrollment into the
study. Comparison of the subgroup of patients that partic-
ipated in the SOLVD Trials (n 5 577) with the subgroup
that participated only in the Registry (n 5 595) demon-
strated that the Registry group had fewer men and conse-
quently, lower body weight. In addition, the Registry group
had a lower frequency of ischemic etiology (by design) and
a higher frequency of NYHA functional class III–IV than
the Trials group (Table 2). The Trials subgroup in the
current investigation resembled the Trial population in
everything but the frequency of an ischemic etiology (79.6%
in the Trial and 68% in the subgroup; p , 0.02). The
Registry subgroup resembled the overall Registry population
in everything but the frequency of NYHA functional class I
(50% in the Registry vs. 33% in the subgroup; p , 0.004).
Mean 6 1 SD, median and range of values for the
echocardiographic measurements are listed in Table 1.
Comparison between Trial and Registry subgroups (Table
1) revealed larger LV dimensions (diastolic and systolic) and
lower EF in the Trial subgroup, and larger LV mass in the
Registry. No differences were observed in LA dimensions.
The one-year all-cause mortality for all patients was 9.5%
with most deaths (84%) being CV in nature (Table 3).
Based on available data, only 44% of the deaths were listed
as secondary to CHF. Forty percent of the patients experi-
enced one or more hospitalizations and 75% of these were
for CV cause of which 38% consisted of CHF.
EF was a strong predictor of events even after adjusting
for age, NYHA functional class, Trials versus Registry and
ischemic etiology. A 1-SD difference in EF was highly
associated with an increase in all-cause mortality (risk ratio
of 1.62 [1.22, 2.14]; p 5 0.0008) and CV hospitalization
(risk ratio of 1.59 [1.27, 2.00]; p 5 0.0001). In addition, an
EF below the mean of 35% was associated with an increased
risk in all-cause mortality (risk ratio of 1.8 [1.01, 3.21], p 5
0.05). Figure 1 illustrates the cumulative mortality rate over
a period of 12 months for patients with EF at or above vs.
below 35%, showing survival advantage for the higher EF
group (p 5 0.012).
Because of the influence of EF on survival, the analysis
for the other echocardiographic variables was adjusted for
EF in addition to age, NYHA class, Trial vs. Registry and
ischemic etiology. A significant relation was observed be-
tween a 1-SD difference in LV mass and all-cause mortality
(risk ratio of 1.3 [1.06, 1.60]; p 5 0.012) as well as CV
hospitalization (risk ratio of 1.17 [1.03, 1.31]; p 5 0.018).
Similar findings were observed with the LA dimension
(mortality: risk ratio, 1.32; p , 0.02; CV hospitalizations:
risk ratio, 1.18; p , 0.04). Neither systolic nor diastolic LV
dimension was associated with higher event rates.
The association of an echo parameter above and below its
mean value to mortality and rate of CV hospitalizations was
examined by Cox proportional hazards regression adjusting
for age, NYHA class, Trial vs. Registry, ischemic etiology
and EF (Table 4). LV mass and LA dimensions greater
than the mean were significantly associated with increased
risk of death and CV hospitalization. End-systolic LV
dimensions larger than the mean were associated with
increased mortality.
Figure 2 illustrates the Kaplan-Meier unadjusted survival
curves (expressed as cumulative one-year mortality) ob-
served in patients with an LV mass at or above vs. below the
mean value of 298 g. Mortality at 1 year reached 12% in
patients with LV mass $298 g and 5% in those with lesser
degree of hypertrophy (p 5 0.0017). The effect of combin-
ing EF with LV mass on mortality rates is graphically
displayed in Figure 3. The log-rank statistic p value (0.0014)
compares the event rate experience of the four groups. An
interaction between EF and LV mass on event rates was
observed for mortality and CV death (Table 5). A protective
effect of EF was noted in the group with LV mass $298 g
(the subgroup with EF .35% fared better), whereas in the
group with LV mass ,298 g, mortality and CV deaths were
lower independent of the EF.
Table 3. Frequency of Events at One Year
All Patients, No.
(%) (n 5 1,172)
Death 111 (9.5)
CV death 93 (7.9)
CHF death 49 (4.2)
Hospitalization 465 (40)
CV hospitalization 351 (30)
CHF hospitalization 132 (11.3)
CV 5 cardiovascular; CHF 5 congestive heart failure.
Figure 1. Kaplan-Meier unadjusted survival curves (expressed as
cumulative 1-year mortality) observed in patients with LVEF at or
above vs. below 35%.
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DISCUSSION
The patients in the SOLVD Registry and Trials were
representative of the spectrum of patients with LV dysfunc-
tion seen in this country. However, by design, ischemic
etiology was underrepresented in the Registry substudy to
allow inclusion of other etiologies of LV dysfunction such as
hypertension, valvular and myocardial diseases. Most pa-
tients (80%) were male and white was the predominant race
(86%), with blacks representing close to 12% of the sample.
From the standpoint of symptoms and LV function, our
study population represented an ambulatory well-
compensated group of patients. Most (85%) were in NYHA
functional class I or II with a mean EF of 35%. Despite this,
the one-year mortality of the group approached 10% with
most of the deaths resulting from a CV event. Furthermore,
40% of the patients experienced one or more hospitaliza-
tions with three quarters of them being CV in nature. As in
many other studies of patients with ischemic, valvular or
myocardial diseases, (1,3,4,32–34), EF was a strong predic-
tor of survival even after adjusting for age, NYHA func-
tional class, Trial vs. Registry and ischemic etiology. For
this reason, the other echocardiographic parameters were
adjusted for EF in addition to the other factors.
This study demonstrates for the first time (to our knowl-
edge) an association between LV hypertrophy and CV
events in patients with chronic LV dysfunction independent
of the presence or absence of heart failure symptoms.
Although increasing LV mass was associated with higher
mortality and rate of CV hospitalizations after adjusting for
EF, an interaction between the two was noted. EF was
protective in patients with LV mass $298 g (the subgroup
with EF .0.35 had lower mortality and CV deaths)
whereas in the group with LV mass ,298 g, mortality and
CV deaths were lower regardless of the EF.
The interaction of myocardial function with LV mass
relative to adverse events has been noted previously in
hypertensive patients by de Simone and associates (35).
They observed the highest event rates in patients who were
in the highest two quartiles of LV mass as well as in those
in the lowest two quartiles of midwall shortening. Further-
more, in patients with increased LV mass, event-free
Table 4. Relation of Echocardiographic Parameters to Event Rate, by Cox Proportional Hazards
Regression
All-Cause Mortality CV Hospitalization
Risk-Ratio*
p
Value Risk-Ratio*
p
Value
LV mass 2.75 (1.62, 4.66) 0.0002 1.81 (1.39, 2.36) 0.0001
LV end-systolic
dimension
2.73 (1.43, 5.20) 0.003 NS NS
LA dimension 1.84 (1.08, 3.15) 0.03 1.37 (1.05, 1.78) 0.02
*Above vs. below the mean group comparison adjusted for age, NYHA class, ischemic etiology and EF.
CV 5 cardiovascular; LV 5 left ventricle; LA 5 left atrium; NYHA 5 New York Heart Association; EF 5 ejection fraction.
Figure 2. Kaplan-Meier unadjusted survival curves (expressed as
cumulative 1-year mortality) observed in patients with LV mass at
or above vs. below the mean value of 298 g.
Figure 3. Kaplan-Meier unadjusted survival curves (expressed as
cumulative 1-year mortality) observed in patients grouped accord-
ing to LV mass and EF. The log-rank statistic p value (0.0014)
compares nonparametrically the event rate experience of the four
groups.
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survival was lower in the subgroup with reduced midwall
shortening. We have observed a similar interaction in
patients with chronic LV dysfunction. Although statistical
associations are not proof of causality, these data are
concordant with the concept that pathologic hypertrophy is
associated with higher rates of CV events (13–19).
Left ventricular remodeling appears to be an important
risk factor for increased mortality in patients with chronic
volume overload lesions and following myocardial infarction
(5,23,32,36,37). In our group of patients, dilatation and
hypertrophy often coexisted with each other and therefore,
the influence of one is closely linked to the other. Never-
theless, LV mass had a statistically stronger association with
adverse events than LV dimensions. This may be due in part
to the inclusion of patients with heart failure and normal EF
(many of whom had hypertension) into the SOLVD Reg-
istry. Thus, relative to Trial patients, the Registry subgroup
had smaller ventricles with higher EF and LV mass (i.e.,
more concentric hypertrophy). It is also possible that the use
of dimensions, instead of volumes, underestimated the
severity of LV dilation (38,39).
Although hypertrophy is often thought as a beneficial
compensation to increased load, there are several factors that
may be detrimental to clinical outcome. Increases in muscle
mass may lead to an imbalance in myocardial oxygen supply
and demand based on a relative reduction in the number of
capillaries, increased intercapillary distance and relative
reduction in energy-producing mitochondria. The expres-
sion of key genes may be altered in the hypertrophic
ventricle and this may lead to abnormalities in function
(40–44). Furthermore, pathologic hypertrophy (in contrast
to physiologic hypertrophy) is associated with increased
collagen deposition in the extracellular matrix and around
the intramyocardial coronary arteries (41,45). The resulting
interstitial and perivascular fibrosis has been linked to
increased LV stiffness and impaired coronary reserve (46–
48), both of which may worsen heart failure and ischemia
(40,41,47,49,50). Therapy with ACE inhibitors has been
shown to partially reverse LV dilation and hypertrophy in
survivors of acute myocardial infarction with depressed LV
function and in patients enrolled in the SOLVD Trials
(51–54). In addition, regression of hypertrophy and im-
provement in EF have been observed in patients with
dilated cardiomyopathy treated with metroprolol (55). All
of these observations combined suggest that regression of
hypertrophy is possible even in advance stages of heart
failure and may be linked to the clinical benefits observed
with ACE inhibitors and beta-adrenergic blocking agents.
Enlargement of the LA, as assessed by the LA dimen-
sion, was also associated with an increased risk of death and
CV hospitalization after adjusting for clinical varables and
EF. This finding is not surprising since the LA dilates
commonly in response to a variety of LV diseases, particu-
larly those associated with hypertrophy and diastolic dys-
function.
Study limitations. The echocardiographic studies were
performed by multiple clinical laboratories with a wide
range of image quality, thus precluding the accurate mea-
surement of LV volumes or the application of the area-
length or truncated ellipsoid methods for the quantification
of LV mass (30). However, the parasternal long axis view
was available in most patients and this allowed for the use of
ventricular dimensions to assess LV size and estimate mass
with the cube formula. In a subgroup of patients from the
SOLVD Trials with echocardiograms of excellent quality,
we observed an excellent correlation between LV mass
derived in this manner with LV mass determined by the
area-length method (28). However, regardless of the equa-
tion used, two-dimensional echocardiography is limited in
its accuracy for measuring LV mass since all methods
assume a uniform thickness of the LV, which is not the case
in areas of chronic infarction or with geometric deformity of
the LV cavity (30,56). Despite its limitations, the method
used in this study was applied in a blinded fashion to a large
sample of patients and thus the association between in-
creased LV mass and CV events is likely to be real.
Table 5. Association of Left Ventricular Mass and Ejection Fraction With Clinical Events
All-Cause
Mortality,
%
Death, % Hospitalization, %
CV CHF Any CV CHF
LV mass ,298 and
EF ,35%
6 5 3 35 24 9
LV mass $298 and
EF ,35%
12 10 5 39 32 18
LV mass ,298 and
EF $35%
4 3 1 27 19 4
LV mass $298 and
EF $35%
6 6 4 39 27 11
CV 5 cardiovascular; CHF 5 congestive heart failure; LV 5 left ventricle; EF 5 ejection fraction.
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CONCLUSIONS
In patients with LV dysfunction enrolled in the SOLVD
Registry and Trials, echocardiographic measurements of LV
mass, LA size and EF were significantly associated with
mortality and rate of CV hospitalizations. A protective
effect of EF was noted in patients with LV mass $298 g,
whereas in the group with smaller mass, mortality was low
irrespective of EF. These findings suggest that in patients
with LV dysfunction (with or without clinical heart failure),
pathologic hypertrophy is associated with higher rates of
adverse CV events and support the development and use of
drugs that inhibit hypertrophy or alter its characteristics.
The echocardiographic measurements obtained in this study
are all within the capacity of any clinical laboratory and thus
are applicable to any patient presenting with LV dysfunc-
tion.
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